Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Research output: Contribution to journalJournal articleResearchpeer-review

Uffe Høgh Olesen, Jakob Gramstrup Petersen, Antje Garten, Wieland Kiess, Jun Yoshino, Shin-Ichiro Imai, Mette Knak Christensen, Peter Fristrup, Annemette Vinding Thougaard, Fredrik Björkling, Peter Buhl Jensen, Søren Jensby Nielsen, Maxwell Sehested

Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.
Original languageEnglish
JournalBMC Cancer
Pages (from-to)677
Number of pages13
Publication statusPublished - 10 Dec 2010

ID: 32331205